Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sarah E. Diver"'
Autor:
P. Jane McDowell, John Busby, Catherine E. Hanratty, Ratko Djukanovic, Ashley Woodcock, Samantha Walker, Timothy Colin Hardman, Joseph R. Arron, David F. Choy, Peter Bradding, Chris E. Brightling, Rekha Chaudhuri, Douglas Cowan, Adel H. Mansur, Stephen J. Fowler, Sarah E. Diver, Peter Howarth, James Lordan, Andrew Menzies-Gow, Timothy Harrison, Douglas S. Robinson, Cecile T. J. Holweg, John G. Matthews, Ian D. Pavord, Liam G. Heaney
Publikováno v:
Am J Respir Crit Care Med
Rationale: The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although present in a minority of pat
Autor:
Freda Yang, John Busby, Liam G. Heaney, Ian D. Pavord, Chris E. Brightling, Katie Borg, Jane P. McDowell, Sarah E. Diver, Rahul Shrimanker, Peter Bradding, Malcolm Shepherd, Rekha Chaudhuri
Publikováno v:
Yang, F, Busby, J, Heaney, L G, Pavord, I, Brightling, C, Borg, K, McDowell, P J, Diver, S E, Shrimanker, R, Bradding, P, Shepherd, M & Chaudhuri, R 2022, ' Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma-a randomised, placebo-controlled crossover trial (MAPLE) ', The Journal of Allergy and Clinical Immunology: In Practice . https://doi.org/10.1016/j.jaip.2022.06.050
Background: Mepolizumab inhibits interleukin-5 (IL-5) activity, reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti-IL-5